{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:42:48Z","timestamp":1776980568576,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T00:00:00Z","timestamp":1385683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Special Research Committee Account of the University of Ioannina","award":["22195"],"award-info":[{"award-number":["22195"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Basal cell carcinoma (<jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content>) is a tumour that relies mainly on aerobic energy assimilation for growth and depends on an extensive microvascular network to support adequate oxygen supply. In this tumour, higher expression levels of vascular endothelial growth factor (<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content>) has been described to correlate with increased microvessel density and more aggressive biologic behaviour.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To report feasibility and effectiveness of intralesional bevacizumab, an anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> antibody, as an in\u2010add adjuvant to immunocryosurgery (cryosurgery sessions during daily topical imiquimod application) for the treatment of locally advanced <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Seven patients (six uncontrollable or extensive local disease; one tumour unresponsive to repeated immunocryosurgery) were treated with 1\u20133 sessions of intralesional injections of bevacizumab (25\u00a0mg) at the day of cryosurgery during ongoing immunocryosurgery. Follow\u2010up after treatment was 18\u201348\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 4\/7 cases tumours cleared completely and 3\/7 remained relapse free during follow\u2010up. A relapsed tumour and a further case that did not clear after repeated immunocryosurgery cycles were excised with significantly reduced burden of surgery. Finally, two cases with previously locally uncontrollable <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content> tumours regressed significantly and stabilized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In\u2010add intralesional bevacizumab is a feasible and potentially effective addition to minimally invasive schemes for the treatment of locally advanced <jats:styled-content style=\"fixed-case\">BCC<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12327","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T12:56:58Z","timestamp":1385729818000},"page":"1117-1121","source":"Crossref","is-referenced-by-count":15,"title":["Intralesional bevacizumab as in\u2010add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma"],"prefix":"10.1111","volume":"28","author":[{"given":"G.","family":"Gaitanis","sequence":"first","affiliation":[{"name":"Department of Skin and Venereal Diseases School of Health Sciences University of Ioannina Ioannina Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.D.","family":"Bassukas","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases School of Health Sciences University of Ioannina Ioannina Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,11,29]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.03.043"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12311"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030750"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-011-1151-y"},{"key":"e_1_2_5_6_1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1684\/ejd.2011.1319","article-title":"Microvessel density and VEGF expression seems to correlate with invasiveness of basal cell carcinoma","volume":"21","author":"Carbone A","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00392.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03224.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1609"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0896"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03562.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2010.495976"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.195800"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12061"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cryobiol.2009.04.011"},{"key":"e_1_2_5_16_1","unstructured":"NCCN Guidelines:Basal cell and squamous cell skin cancers. Version 1.2013. URLhttps:\/\/subscriptions.nccn.org\/gl_login.aspx?ReturnURL=http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nmsc(last accessed: 15 July 2013)."},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2013.1810"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.572"},{"key":"e_1_2_5_19_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/jop.2011.0244","article-title":"Intralesional bevacizumab use for invasive ocular surface squamous neoplasia","volume":"28","author":"Paul S","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-5224.2012.01051.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.403"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12327","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:13:57Z","timestamp":1695554037000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,29]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/jdv.12327"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12327","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,29]]}}}